Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease

European Journal of Preventive Cardiology

Volumn 13, Issue 2, 2006, Pages 274-280

  Quist Paulsen, Petter ^a   Lydersen, Stian ^b   Bakke, Per S ^c   Gallefoss, Frode ^d  

^a SØRLANDET HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d Sorlandet Hospital Kristiansand   (Norway)

Author keywords

coronary heart disease; cost effectiveness analysis; myocardial infarction; smoking cessation; unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH PROGRAM; HEART REHABILITATION; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SMOKING CESSATION; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

ADULT; ANGINA, UNSTABLE; CORONARY DISEASE; COSTS AND COST ANALYSIS; HUMANS; LIFE EXPECTANCY; MYOCARDIAL INFARCTION; NORWAY; RISK ASSESSMENT; SMOKING CESSATION; SURVIVAL ANALYSIS;

EID: 33746209277     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000192742.81231.91     Document Type: Article

References (28)

1. Critchley JA, Capewell MD. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. JAMA 2003; 290: 86–97.
2. Daly LE, Mulcahy R, Graham IM, Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983; 287: 324–326.
3. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990; 113: 118–123.
4. Quist-Paulsen P, Gallefoss F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 2003; 327: 1254–1257.
5. Dornelas EA, Sampson RA, Gray JF, Waters D, Thompson PD. A randomized controlled trial of smoking cessation counselling after myocardial infarction. Prev Med 2000; 30: 261–268.
6. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22: 1697–1702.
7. Van Domburg RT, Meeter K, van Berkel DFM, Veldkamp RF, van Herwerden LA, Bogers JJC. Smoking cessation reduces mortality after coronary artery bypass surgery: A 20-year follow-up study. J Am Coll Cardiol 2000; 36: 878–883.
8. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faegeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771–777.
9. Lawless JF. Statistical models and methods for lifetime data. 2nd ed. New Jersey: Wiley, Hoboken; 2003.
10. Baigent C, Collins R, Appleby P. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both or neither. BMJ 1998; 316: 1337–1343.
11. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med 1982; 73: 883–897.
12. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, part I: general principles. Prog Cardiovasc Dis 1994; 37: 161–184.
13. Johannesson M, Jønsson B, Kjekshus J, Olsson A, Pedersen TR, Wedel H. For the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332–336.
14. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800–1806.
15. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300–1303.
16. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2001.
17. Probstfield JL. How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol 2003; 91 (Suppl):22G–27G.
18. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997; 17: 222–231.
19. Quist-Paulsen P, Bakke PS, Gallefoss F. Predictors of smoking cessation in patients admitted for acute coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 5: 472–478.
20. Sivarajan Froelicher ES, Miller NH, Christopherson DJ, Martin K, Parker KM, Amonetti M, et al. High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation 2004; 109: 587–593.
21. Van Berkel TFM, Boersma H, Roos-Hesselink JW, Erdman RAM, Simoons ML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J 1999; 20: 1773–1782.
22. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001; 85: 539–543.
23. Jorgensen Kober L., Ottesen MM, Torp-Pedersen C, Videbaek J, Kjoller E. The prognostic importance of smoking status at the time of acute myocardial infarction in 6676 patients. TRACE Study Group. J Cardiovasc Risk 1999; 6: 23–27.
24. Woodward M, Tunstall-Pedoe H. Biochemical evidence of persistent heavy smoking after a coronary diagnosis despite self-reported reduction: analysis from the Scottish Heart Health Study. Eur Heart J 1992; 13: 160–165
25. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336: 755–761.
26. Mølstad P, Andersen K. Reduction in mortality after myocardial infarction [in Norwegian]. Tidsskr Nor Laegeforen 2002; 122: 1271–1275.
27. Hajek P, Taylor TZ, Mills P. Brief intervention during hospital admission to help patients to give up smoking after myocardial infarction and bypass surgery: randomised controlled trial. BMJ 2002; 324: 87–89.
28. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003; 326: 84.